Divalproex sodium Alternatives Compared
| Divalproex sodium | Vraylar (cariprazine) | Caplyta (lumateperone) |
|
|---|
| Divalproex sodium | Vraylar (cariprazine) | Caplyta (lumateperone) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Divalproex may be used for the treatment of absence or partial seizures, as a preventive treatment for migraines, and to treat mania associated with bipolar disorder. Divalproex may adversely and... View more |
Prescription only
Vraylar is an atypical antipsychotic that is effective for the treatment of schizophrenia and bipolar I disorder. Vraylar is usually well-tolerated and less likely than some other antipsychotics to... View more |
Prescription only
Caplyta is an atypical antipsychotic that is used to treat adults with schizophrenia or depression associated with bipolar disorder. Sleepiness is the most common side effect and it should not be... View more |
Related suggestions Bipolar Disorder
Popular comparisons
|
|||||||||||||||||||||||
| More about Divalproex sodium | More about Vraylar (cariprazine) | More about Caplyta (lumateperone) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Divalproex sodium has an average rating of 6.6 out of 10 from a total of 513 ratings on Drugs.com. 53% of reviewers reported a positive effect, while 23% reported a negative effect. |
Vraylar has an average rating of 6.1 out of 10 from a total of 534 ratings on Drugs.com. 49% of reviewers reported a positive effect, while 32% reported a negative effect. |
Caplyta has an average rating of 6.6 out of 10 from a total of 189 ratings on Drugs.com. 56% of reviewers reported a positive effect, while 28% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Divalproex sodium side effects |
View all Vraylar side effects |
View all Caplyta side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Divalproex sodium prices |
View all Vraylar prices |
View all Caplyta prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Depakote, Depakote ER, Depakote Sprinkles |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
16 hours |
504 hours |
18 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category D
Positive evidence of risk
When Treating Epilepsy And Manic Episodes Associated With Bipolar Disorder
Category X
Not for use in pregnancy
When Treating Migraine See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 426 drugs are known to interact with Divalproex sodium:
|
A total of 579 drugs are known to interact with Vraylar:
|
A total of 606 drugs are known to interact with Caplyta:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
March 10, 1983 |
September 17, 2015 |
December 20, 2019 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.